Results of SWOG 1318: A Phase 2 Trial of Blinatumomab Followed By Pomp (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) Maintenance in Elderly Patients with Newly Diagnosed Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia
Anjali S. Advani(Cleveland Clinic), Harry P. Erba(Michigan Center for Translational Pathology), Rupali Bhave(Atrium Health Wake Forest Baptist), Kristen M. O’Dwyer(University of Rochester Medical Center), Brent L. Wood(University of Southern California), Anna Moseley(Fred Hutch Cancer Center), Megan Othus(Cancer Research And Biostatistics), Rebecca B. Klisovic(Goethe University Frankfurt), Ibrahim Aldoss(City of Hope), Min Fang(Zhejiang International Studies University), Maria R. Baer(University of Maryland, Baltimore), Richard M. Stone(Dana-Farber Cancer Institute), Mark R. Litzow(Mayo Clinic in Arizona), Wendy Stock(University of Chicago), Jae H. Park(Memorial Sloan Kettering Cancer Center), Matthew J. Wieduwilt(Atrium Health Wake Forest Baptist)
Cited by 40
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k